Randomized Phase II Study of Gemcitabine (GEM) Versus GEM+TS-1 for Advanced Pancreatic Cancer

Trial Profile

Randomized Phase II Study of Gemcitabine (GEM) Versus GEM+TS-1 for Advanced Pancreatic Cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Jun 2017

At a glance

  • Drugs Gimeracil/oteracil/tegafur (Primary) ; Gemcitabine
  • Indications Pancreatic cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 18 Jan 2014 Pooled results for prognostic factors from GEST, GEMSAP, and JACCRO PC-01 presented at the 2014 Gastrointestinal Cancers Symposium.
    • 01 May 2012 Primary endpoint 'Objective-clinical-response-rate' has been met according to results published in Cancer Chemotherapy and Pharmacology.
    • 01 May 2012 Results published in Cancer Chemotherapy and Pharmacology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top